Chinese RNA-based medicine developer Suzhou Ribo Life Science has filed a Hong Kong IPO, aiming to raise new funds for its lead RBD4059 drug candidate for thrombotic diseases. The small-interfering ...

The cancer gene MYC camouflages tumours by suppressing alarm signals that normally activate the immune system. This finding from a new study offers ...